Checkpoint inhibitor completes preclinical investigation
by Guest Author
Feb 24, 2016: Regen BioPharma, Inc., announced today the completion of experiments, in collaboration with PNI Neuro-oncologist and JWCI researcher, Dr. Santosh Kesari, demonstrating immunological mechanisms of its novel NR2F6 gene silencing approach. The Company has begun the process of compiling an Investigational New Drug Application (IND) with the FDA for testing this approach in cancer patients. Earlier this month the Company announced the filing of patent applications covering two new immunological pathways that could lead to more potential treatment options for fighting cancer.
The results show that blocking the checkpoint inhibitor gene target NR2F6, allows the increased production of key immune system proteins interleukin-17 and interleukin-18. Both play important roles in boosting immune response and killing cancer cells.
Checkpoint inhibitors are a class of cancer immunotherapy treatments, which enhance or restore the function of the immune system against cancer cells in the body. The data in pre-clinical models, suggest that therapeutics developed through this NR2F6-gene-silencing program could be used alone or along with other existing checkpoint inhibitor therapies.
Dr. Santosh Kesari serves as the Professor of Neurosciences and Chair of the Department of Neuro-oncology and Neurotherapeutics at the Saint John’s Cancer Institute at Providence Saint John’s Health Center.
Last updated: January 6th, 2020